Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis

The Lancet Haematology

Volumn 3, Issue 2, 2016, Pages e80-e86

  Conter, Valentino ^a   Valsecchi, Maria Grazia ^b   Buldini, Barbara ^c   Parasole, Rosanna ^d   Locatelli, Franco ^e,f   Colombini, Antonella ^a   Rizzari, Carmelo ^a   Putti, Maria Caterina ^c   Barisone, Elena ^g   Nigro, Luca Lo ^h   Santoro, Nicola ⁱ   Ziino, Ottavio ^j   Pession, Andrea ^k   Testi, Anna Maria ^l   Micalizzi, Concetta ^m   Casale, Fiorina ⁿ   Pierani, Paolo ^o   Cesaro, Simone ^p   Cellini, Monica ^o   Silvestri, Daniela ^a,b   Cazzaniga, Giovanni ^a   Biondi, Andrea ^a   Basso, Giuseppe ^c   more..

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^h Azienda Policlinico   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j ARNAS Ospedali Civico di Cristina e Benfratelli   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m G GASLINI INSTITUTE   (Italy)

ⁿ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^o Department of Pediatric Hemato Oncology ^*  (Italy)

^p UNIVERSITY HOSPITAL OF VERONA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; METHOTREXATE; PREDNISONE; SORAFENIB; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CHILD; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; IMMUNOPHENOTYPING; INFANT; ITALY; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOPHENOTYPING; INFANT; ITALY; MALE; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84957998959     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00254-9     Document Type: Article

References (13)

1. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009, 10:147-156.
2. Patrick K, Wade R, Goulden N, et al. Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014, 166:421-424.
3. Wood BL, Winter SS, Dunsmore KP, et al. T-lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in children's oncology group (COG) study AALL0434. Blood 2014, 124. abstr 1.
4. Conter V, Valsecchi MG, Buldini B, et al. Outcome of early T-cell precursor acute lymphoblastic leukemia in AIEOP patients treated with the AIEOP-BFM ALL 2000 study. Blood 2014, 124. abstr 3780.
5. Inukai T, Kiyokawa N, Campana D, et al. Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol 2012, 156:358-365.
6. Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011, 118:2077-2084.
7. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010, 115:3206-3214.
8. D'Angiò M, Valsecchi MG, Testi AM, et al. Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group. Hematologica 2015, 100:e10-e13.
9. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009, 27:5168-5174.
10. Wu D, Sherwood A, Fromm JR, et al. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012, 4:134ra63.
11. Neumann M, Heesch S, Gökbuget N, et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2012, 2:e55.
12. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481:157-163.
13. Vora A, Goulden N, Mitchell C, et al. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Lancet Oncol 2014, 15:809-818.